{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE297nnn/GSE297057/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297057"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Multi-omics analysis in EGFR-mutant lung adenocarcinoma","description":"Using genomic and transcriptomic anaysis, we have identified TP53-GOF mutations as key genomic alterations associated with early resistance to first-line osimertinib therapy in EGFR-mutant NSCLC. Through comprehensive genomic and transcriptomic profiling, we found that TP53-GOF mutations define a biologically distinct subgroup marked by significantly shorter progression-free survival against osimrtinib treatment.","dates":{"publication":"2026/05/11"},"accession":"GSE297057","cross_references":{"GSM":["GSM8982761","GSM8982762","GSM8982760","GSM8982747","GSM8982748","GSM8982745","GSM8982746","GSM8982765","GSM8982743","GSM8982766","GSM8982744","GSM8982763","GSM8982741","GSM8982742","GSM8982764","GSM8982750","GSM8982751","GSM8982758","GSM8982759","GSM8982756","GSM8982757","GSM8982754","GSM8982755","GSM8982752","GSM8982753","GSM8982749"],"GPL":["34284"],"GSE":["297057"],"taxon":["Homo sapiens"]}}